Alzamend Neuro Inc (ALZN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Alzamend Neuro Inc (ALZN) has a cash flow conversion efficiency ratio of -0.795x as of January 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.74 Million) by net assets ($2.18 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ALZN cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Alzamend Neuro Inc - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Alzamend Neuro Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Alzamend Neuro Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Alzamend Neuro Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Link Bilgisayar Sistemleri Yazilimi ve Donanimi Sanayi ve Ticaret AS
IS:LINK
|
0.021x |
|
Franchise Brands PLC
LSE:FRAN
|
0.043x |
|
Sherpa II Holdings Corp
V:SHRP
|
-0.046x |
|
H&T Group plc
LSE:HAT
|
0.033x |
|
Power REIT
NYSE MKT:PW
|
-0.035x |
|
SaverOne 2014 Ltd. American Depositary Shares
NASDAQ:SVRE
|
-1.130x |
|
FW Thorpe PLC
LSE:TFW
|
0.081x |
|
BrightBid Group AB (publ)
ST:PERP-B
|
-0.045x |
Annual Cash Flow Conversion Efficiency for Alzamend Neuro Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Alzamend Neuro Inc from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Alzamend Neuro Inc worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-04-30 | $3.97 Million | $-6.57 Million | -1.655x | -151.92% |
| 2024-04-30 | $-2.59 Million | $-8.27 Million | 3.188x | +208.80% |
| 2023-04-30 | $3.05 Million | $-8.92 Million | -2.930x | -491.46% |
| 2022-04-30 | $13.35 Million | $-6.61 Million | -0.495x | +63.23% |
| 2021-04-30 | $2.01 Million | $-2.71 Million | -1.347x | +52.81% |
| 2020-04-30 | $821.71K | $-2.35 Million | -2.855x | +13.44% |
| 2019-04-30 | $316.92K | $-1.05 Million | -3.298x | -272.82% |
| 2018-04-30 | $2.32 Million | $-2.05 Million | -0.885x | -136.52% |
| 2017-04-30 | $-584.93K | $-1.42 Million | 2.422x | -98.61% |
| 2016-04-30 | $-106.00 | $-18.49K | 174.453x | -- |
About Alzamend Neuro Inc
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neur… Read more